Van Cutsem, E <br/><br/>
A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  Oct 2015 
 - 2085-91 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdv286  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Bevacizumab--administration & dosage<br/>Colorectal Neoplasms--drug therapy<br/>Female<br/>Fluorouracil--administration & dosage<br/>Follow-Up Studies<br/>Humans<br/>Indoles--administration & dosage<br/>Leucovorin--administration & dosage<br/>Male<br/>Middle Aged<br/>Neoplasm Metastasis<br/>Neoplasm Staging<br/>Organoplatinum Compounds--administration & dosage<br/>Oxaliplatin<br/>Prognosis<br/>Survival Rate